- Conditions
- COPD
- Interventions
- Inhaled PT005, Inhaled Placebo, Formoterol Fumarate 12 µg (Foradil Aerolizer)
- Drug
- Lead sponsor
- Pearl Therapeutics, Inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Spartanburg, South Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1921–1944
of 12,606
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Not listed
- Lead sponsor
- Megan Ballinger
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2018
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Sedentary Lifestyle, Self Efficacy, Control Locus, Aging
- Interventions
- App Experimental condition, App Condition Control
- Behavioral
- Lead sponsor
- Brandeis University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Waltham, Massachusetts
- Conditions
- Overactive Bladder
- Interventions
- Vibegron, placebos, Tolterodine Tartrate ER
- Drug
- Lead sponsor
- Urovant Sciences GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 506 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 107
- States / cities
- Mobile, Alabama • Tempe, Arizona • Tucson, Arizona + 90 more
- Conditions
- Health Behavior, Obesity
- Interventions
- SMS Text Messages & Fitbit One, Fitbit One Only
- Behavioral
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Scleroderma
- Interventions
- Mindfulness Based Stress Reduction (MBSR), Control
- Behavioral · Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Complicated Skin and Skin Structure Infections
- Interventions
- JNJ-32729463, linezolid, JNJ-32729463 placebo, linezolid placebo
- Drug
- Lead sponsor
- Furiex Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 27
- States / cities
- Anaheim, California • Buena Park, California • Chula Vista, California + 23 more
- Conditions
- Tetralogy of Fallot (TOF), Hypoplastic Left Heart Syndrome (HLHS)
- Interventions
- 3D-printed heart models and augmented reality
- Other
- Lead sponsor
- Case Western Reserve University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- ADRD, Alzheimer's Disease, Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD), Health Behavior, Healthy Aging, Vascular Health
- Interventions
- TEACH, Basic health education
- Behavioral
- Lead sponsor
- Rhode Island Hospital
- Other
- Eligibility
- 40 Years to 69 Years
- Enrollment
- 280 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2027 – 2031
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Hypoactive Sexual Desire Disorder
- Interventions
- Bremelanotide, Placebo
- Drug · Other
- Lead sponsor
- Palatin Technologies, Inc
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 723 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 87
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 79 more
- Conditions
- Coronary Artery Disease, Hypertriglyceridemia
- Interventions
- pradigastat (LCQ908), Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Pasadena, California
- Conditions
- Health Behavior, Health Care Utilization
- Interventions
- Promotores de Salud, Services as usual
- Behavioral
- Lead sponsor
- University of Oregon
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 1,623 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Eugene, Oregon
- Conditions
- Opioid Overdose, Drug Overdose
- Interventions
- PROVIDENT
- Behavioral
- Lead sponsor
- Brown University
- Other
- Eligibility
- Not listed
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Marginal Zone Lymphoma, Refractory Transformed B-Cell Non-Hodgkin Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma, Recurrent Central Nervous System Lymphoma, Refractory Central Nervous System Lymphoma
- Interventions
- Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Laboratory Biomarker Analysis, Leukapheresis, Fludarabine Phosphate
- Biological · Drug · Other + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2039
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Hereditary Spastic Paraplegia Type 50
- Interventions
- MELPIDA
- Genetic
- Lead sponsor
- Elpida Therapeutics SPC
- Industry
- Eligibility
- 4 Months to 72 Months
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Erosive Esophagitis
- Interventions
- X842, X842 Dummy, Lansoprazole, Lansoprazole Dummy
- Drug
- Lead sponsor
- Cinclus Pharma Holding AB
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Fragile X Syndrome, FXS, Fra(X) Syndrome
- Interventions
- BPN14770, Placebo
- Drug
- Lead sponsor
- Tetra Discovery Partners
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Healthy Participants
- Interventions
- Workload of Manual Wheelchair Propulsion
- Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Homewood, Alabama
- Conditions
- Dysbiosis
- Interventions
- Goya Foods - Canned Chickpeas, Goya Foods - Canned Lentils, Control
- Other
- Lead sponsor
- Florida State University
- Other
- Eligibility
- 18 Years to 30 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Tallahassee, Florida
- Conditions
- Post Traumatic Stress Disorder PTSD
- Interventions
- NurseNET, Referral to PTSD Treatment
- Behavioral
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Brookfield, Wisconsin
- Conditions
- Oral Cavity Squamous Cell Carcinoma, Oropharynx Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of the Head and Neck
- Interventions
- OncAlert
- Device
- Lead sponsor
- Joseph Califano
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2022
- U.S. locations
- 4
- States / cities
- La Jolla, California • Baltimore, Maryland • New York, New York
- Conditions
- Alzheimer's Disease (AD)
- Interventions
- ABBV-552, Placebo for ABBV-552
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 37
- States / cities
- Irvine, California • Long Beach, California • Los Alamitos, California + 31 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Pamrevlumab, Placebo, Sub-Study: Pirfenidone, Sub-Study: Nintedanib
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 23 more
- Conditions
- Schizophrenia, Schizo-affective Disorder
- Interventions
- Illness Management and Recovery, Problem Solving
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana